Frame Ltd.

DUBLIN--( BUSINESS WIRE )--The "Ultrafiltration Market Size, Share, Trends, By Type, By Module, By Application, and By Region Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. The global ultrafiltration market is forecast to reach USD 5.72 Billion by 2030, according to this report. Ultrafiltration is a pressure-driven separation process that uses membrane technology to separate macromolecules and colloids from a solution on the basis of molecular weight. Increasing demand for safe drinking water, rapid industrialization and urbanization, stringent government regulations regarding wastewater discharge, and technological advancements are expected to fuel market growth during the forecast period. The market is anticipated to gain significant momentum in the next few years owing to the growing need for clean and safe water. In addition, rising awareness about the benefits of ultrafiltration, such as its ability to remove contaminants from water, is expected to boost market growth in the coming years. Furthermore, increasing investment by leading companies in research and development activities is expected to create new opportunities for market expansion in the near future. Technological advancement is one of the key trends being witnessed in the ultrafiltration market. Membrane manufacturers are continuously investing in research and development to develop new and improved membranes with higher flux and better selectivity. In December 2017, DowDuPont Inc. announced the launch of its new product, the FILMTECT EC-LM (Enhanced Chemistry - Low Minerals) Element. This product is designed for use in low-mineral water applications and offers high flux and stable operation. Further key findings from the report suggest In terms of application, the ultrafiltration market has been categorized into drinking water treatment, wastewater treatment, process water treatment, and others. Among these, the wastewater treatment application segment is anticipated to grow at the highest CAGR during the forecast period. The ultrafiltration market has been classified on the basis of membrane type into polymeric, ceramic, and others. The polymeric membranes segment is anticipated to grow at the highest CAGR during the forecast period. This is due to their low cost and easy availability as compared to other membrane types. On the basis of module type, the ultrafiltration market has been classified into cassette modules, plate-and-frame modules, and others. The plate-and-frame modules segment is anticipated to grow at the highest CAGR during the forecast period. This is due to their ability to provide a larger surface area for filtration, thereby increasing the efficiency of the overall process. The ultrafiltration market has been segmented on the basis of end-use industry into municipal, power, food & beverage, pharmaceuticals, oil & gas, and others. The municipal application segment is anticipated to grow at the highest CAGR during the forecast period due to the increasing demand for clean water from urban areas. Geographically, the ultrafiltration market has been segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. Among these regions, Asia Pacific is expected to grow at the highest CAGR during the forecast period due to the rapid industrialization and urbanization in the region. Companies Mentioned Pentair DuPont Parker-Hannifin Corporation Pall Corporation Koch Separation Solution 3M Hydranautics PCI Membranes Toray Industries Inc. Alfa Laval For the purpose of this report, the author have segmented into the global Ultrafiltration market on the basis of type, module, application, and region: Type Outlook (Revenue, USD Billion; 2019-2030) Polymeric Ceramic Module Outlook (Revenue, USD Billion; 2019-2030) Hollow Fiber Plate and Frame Tubular Others Application Outlook (Revenue, USD Billion; 2019-2030) Municipal Treatment Industrial Treatment Food & Beverage Processing Pharmaceutical Processing Chemical & Petrochemical Processing Others Regional Outlook (Revenue, USD Billion; 2019-2030) North America U.S. Canada Mexico Europe Germany U.K. France Italy Spain Sweden BENELUX Rest of Europe Asia-Pacific China India Japan South Korea Rest of APAC Latin America Brazil Rest of LATAM Middle East & Africa Saudi Arabia UAE South Africa Israel Rest of MEA For more information about this report visit https://www.researchandmarkets.com/r/swgmim

Solera's new Women's Health Network expands its extensive suite of value-based digital and community-based health programs to address the broad spectrum of women's health issues PHOENIX, Oct. 27, 2022 /PRNewswire/ -- Solera Health, the premier platform for connecting people seamlessly to proven and personalized health solutions, announces the launch of a first-of-its-kind Women's Health network of digital point solutions. Solera's new network covers the spectrum of women's health needs, including those underserved by the market today, filling critical gaps in care to bring more access to women who need it. Continue Reading Solera's Women's Health Network "Women's health needs extend beyond fertility and maternity, and we have purposefully built a network that spans the lifecycle of women's unique health needs, from pelvic floor dysfunction to menopause," said Mary Langowski, CEO of Solera Health. "Women's health continues to be one of the most underserved segments in our healthcare system and we are excited to expand our offerings to address some of the most prevalent health disorders women are facing today." Solera conducted extensive user research and found that 68% of women agree that women's health doesn't get enough attention. Furthermore, 87% of women are very or extremely interested in at least one of the tools Solera offers and 79% would like to use more than one solution at the same time, indicating that one size does not fit all for women's health. Solera's Women's Health network will begin with five partner solutions: Frame Fertility, Origin, Pacify, RestoreBalance and Visana. This network has been carefully vetted and curated to bring the best possible solutions together in one place to address women's physical, behavioral, and social needs at each life stage. These solutions serve as a strong complement to leading maternal offerings to help a health plan or employer better serve the needs of all women in its population through a single contract and IT integration. Solera's clinical AI and personalized matching experience pairs program participants with their best-fit program based on their clinical needs and personal preferences. This approach enables each woman to get the care they need, when and where they prefer. Furthermore, Solera's value-based payment model best aligns member engagement with clinical outcomes. "Solera's Women's Health network is a clinically inclusive and expansive offering, addressing key women's health needs at every age, leading to a more satisfied, productive workforce that feels empowered and supported," continued Langowski. "Solera's new suite of evidence-based women's health programs continues our mission of bringing the best solutions to address the diverse clinical needs of our member populations. We are committed to ensuring that every individual receives the personalized care needed to achieve superior outcomes at a lower cost." About Frame Fertility Frame Fertility is the first evidence-based, comprehensive platform that enables the early detection of risk and care navigation to inform family building and planning. Developed with clinical experts, Frame's approach alleviates a downstream and often costly health crisis for patients, employers, and payers. Founded by a wife and husband team that went through their own challenging fertility journey, Frame seeks to displace reactive, one-size-fits-all family planning models, offering a new way forward with tailored resources and expert support from coaches who get where you're coming from and lead you where you want to go. Frame supports people of all races, ethnicities, gender identities and sexual orientations, both single and partnered. For more information, visit framefertility.com. About HealthFleet RestoreBalance, a HealthFleet program, is a coach-led digital menopause support program. As part of HealthFleet's Restore Family of Products, RestoreBalance tackles the core issues so women in the workforce can feel in control of their day-to-day wellbeing with confidence. With greater than 30 symptoms and thousands of women diagnosed daily, menopause affects individuals, families, and organizations collectively. Such a large population cannot go unsupported. RestoreBalance is a digital menopausal support program with live coaching for education, accountability, and habit building. HealthFleet offers solutions that blend technology, people, and content to deliver impactful programs such as RestoreBalance. This includes personalized, actionable support for individuals that address health issues before they escalate. To learn more about HealthFleet's RestoreBalance program, visit us at . About Origin Origin is a leading provider of pelvic floor and whole-body physical therapy with a specialized focus on pregnancy, postpartum, menopause, and sexual health. Origin offers virtual and in-person PT sessions, covered by insurance, and supported by proprietary exercise programs, educational content, and community experiences. Origin is building a category-defining brand that establishes a higher standard of care for every woman and individual with vaginal anatomy. In addition to in-person locations in Los Angeles, San Francisco, and Austin, Origin provides virtual care throughout the country. Expansion continues, with new clinics in Texas set to open in early 2023. For more information, please visit or @theoriginway. About Pacify Pacify provides 24/7 infant feeding and doula support to new and expecting parents. Pacify's nationwide network of IBCLCs and maternal health experts help families within minutes, reducing costs and improving outcomes for partners including WIC programs, Departments of Health, home visiting programs, managed care organizations, hospitals, non-profit organizations and employers. Learn more by visiting . About Visana Visana is elevating the standard of women's healthcare. Founded in 2019 by CEO Joe Connolly, Visana is a virtual-first clinic that provides whole-person clinical care for the widest range of women's health conditions. From menstruation to menopause, Visana goes beyond the narrow focus on maternity to offer the most comprehensive care for all phases of a woman's life. Visana coordinates with in-person providers for seamless end-to-end care and provides holistic support for women, including health coaching and personalized care plans. For more information, visit . About Solera Solera Health is changing lives by guiding people to better health solutions that work. Leveraging a dynamic digital platform, the company provides intensive, evidence-based lifestyle, behavioral and social interventions, impacting the most prevalent and costly chronic conditions across various acuity levels. Solera strategically matches consumers to their best-fit solution within carefully curated and vetted networks of digital and community-based point solutions all implemented via an innovative, value-based payment model. The company's suite of condition program offerings includes Diabetes Prevention & Management, Falls Prevention, Hypertension, Mental & Behavioral Health, Musculoskeletal, Tobacco Cessation and Weight Management. Moreover, Solera's world-class solution handles challenging administrative tasks, including claims processing, compliance, consumer engagement, eligibility checking, member matching and vendor management, giving payers and employers access to dozens of point solutions with just one contract and one technical integration. For more information, visit . Media Contact: Coleman Pyeatt anthonyBarnum Public Relations [email protected] (214) 797-9848 SOURCE Solera Health

Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. "The addition of Frame's technology and talent to CureVac's oncology research complements our ability to identify and validate promising neoantigens for our mRNA cancer vaccine programs," said Franz-Werner Haas, Chief Executive Officer of CureVac. "The bioinformatics platform developed by Frame's researchers has the potential to identify a broad panel of neoantigens that go beyond conventional neoantigens and could strongly increase the likelihood of developing highly effective cancer vaccines. We are excited to join forces with the innovative Frame Cancer Therapeutics team and combine their bioinformatics capabilities with our own mRNA expertise to potentially deliver a new class of cancer vaccines." Frame's FramePro platform identifies structural changes within the cancer genome that give rise to new open reading frames. These new open reading frames result in novel proteins that are absent in healthy tissues and can thereby be recognized as foreign by the immune system. Although these genetic changes are highly specific to individuals, the resulting neoantigenic proteins may be shared among many patients, potentially enabling development of more broadly applicable cancer vaccines. An additional application of Frame's technology is the development of personalized cancer vaccines, thereby leveraging the full antigenic potential of a tumor. In December 2021, regulators in the Netherlands approved Frame's clinical trial protocol to evaluate this approach based on a peptide vaccine in 15 patients with non-small cell lung cancer. CureVac will refocus development of personalized cancer vaccines on an mRNA modality. "We are very enthusiastic about the great synergies between our content-driven approach in antigen discovery and validation and CureVac's extensive experience with mRNA vaccine development," said Ronald Plasterk, Founder and CEO of Frame Cancer Therapeutics. "The resulting vaccines could greatly enhance our ability to activate the human immune system against cancer, both in a personalized and off-the-shelf manner." The total consideration for the acquisition of Frame Therapeutics is valued at €32 million. It will be paid in CureVac shares. Following a 50 percent upfront payment, the residual amount will be split across two project milestone driven steps. CureVac will expand the antigen discovery and validation activities at the Amsterdam Science Park. About CureVac CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at About Frame Cancer Therapeutics Frame Cancer Therapeutics is a privately funded startup company in the Amsterdam Science Park founded in December 2018. Frame Therapeutics' goal is to develop its proprietary approach for immunotherapy against cancer, which is based on precise analysis of the DNA and RNA of the tumor of a patient and using that information to supply the best vaccine against properties specific for the tumor. The strong anti-tumor immune response elicited by Frame vaccines may contribute to major clinical benefits for patients with diverse forms of cancer. CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations CureVac, Tübingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949 sarah.fakih@curevac.com CureVac Media Relations Contact Bettina Jödicke-Braas, Manager Communications CureVac, Tübingen, Germany T +49 7071 9883-1087 bettina.joedicke-braas@curevac.com Frame Cancer Therapeutics Media Relations Contact Eva Daems, Operations Manager Frame Cancer Therapeutics, Amsterdam, the Netherlands M: +31 6 45 25 94 04 eva.daems@frametherapeutics.com Forward-Looking Statements CureVac This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH and CureVac RNA Printer GmbH (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at . SOURCE: CureVac View source version on accesswire.com: